Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study

References

• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2016 Available from: www.ginasthma.org.Accessed 1211, 2019.
   Google Scholar
• De Marco R, Cappa V, Accordini S, et al. Trends in the prevalence of asthma and allergic rhinitis in Italy between 1991 and 2010. Eur Respir J. 2012;39:883–892. doi:10.1183/09031936.0006161122005911
   PubMed Web of Science ®Google Scholar
• Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008;372:1107–1119. doi:10.1016/S0140-6736(08)61452-X18805339
   PubMed Web of Science ®Google Scholar
• Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181:315–323. doi:10.1164/rccm.200906-0896OC19892860
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. 2019 Available from: www.ginaasthma.org. Accessed 1211, 2019.
   Google Scholar
• Accordini S, Corsico A, Cerveri I, et al. The socioeconomic burden of asthma is substantial in Europe. Allergy. 2008;63:116–124. doi:10.1111/j.1398-9995.2007.01523.x18053021
   PubMed Web of Science ®Google Scholar
• Chastek B, Korrer S, Nagar SP, et al. Economic burden of illness among patients with severe asthma in a managed care setting. J Manag Care Spec Pharm. 2016;22(7):848–861. doi:10.18553/jmcp.2016.22.7.84827348285
   PubMedGoogle Scholar
• Colice G, Wu EQ, Birnbaum H, Daher M, Marynchenko MB, Varghese S. Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population. J Occup Environ Med. 2006;48(8):794–802. doi:10.1097/01.jom.0000229819.26852.0e16902372
   PubMed Web of Science ®Google Scholar
• Custovic A, Johnston SL, Pavord I, et al. EAACI position statement on asthma exacerbations and severe asthma. Allergy. 2013;68(12):1520–1531. doi:10.1111/all.2013.68.issue-1224410781
   PubMed Web of Science ®Google Scholar
• Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1. doi:10.1186/s40733-016-0029-328078100
   PubMedGoogle Scholar
• Melero Moreno C, Quirce S, Huerta A, et al. Economic impact of severe asthma in Spain: multicentre observational longitudinal study. J Asthma. 2019;56(8):861–871. doi:10.1080/02770903.2018.149903530003827
   PubMed Web of Science ®Google Scholar
• Pedrini A, Rossi E, Calabria S, et al. Current management of severe refractory asthma in Italy: analysis of real-world data. Glob Reg Health Technol Assess. 2017;4(1):e216–e220.
   Google Scholar
• Gruffydd-Jones K, Thomas M, Roman-Rodríguez M, et al. Asthma impacts on workplace productivity in employed patients who are symptomatic despite background therapy: a multinational survey. J Asthma Allergy. 2019;12:183–194. doi:10.2147/JAA.S20427831372003
   PubMed Web of Science ®Google Scholar
• Senna G, Guerriero M, Paggiaro PL, et al. SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma. Clin Mol Allergy. 2017;15:9. doi:10.1186/s12948-017-0065-428400707
   PubMedGoogle Scholar
• Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J. 2002;19(1):61–67. doi:10.1183/09031936.02.0023200111843329
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Bergman R, Birnbaum HG, Colice GL, Silverman RA, McLaurin K. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. J Allergy Clin Immunol. 2012;129(5):1229–1235. doi:10.1016/j.jaci.2012.01.03922326484
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Rasouliyan L, Russo PA, Kamath T, Chipps BE, Group TS. Extent, patterns, and burden of uncontrolled disease in severe or difficult to- treat asthma. Allergy. 2007;62(2):126–133. doi:10.1111/j.1398-9995.2006.01254.x17298420
   PubMed Web of Science ®Google Scholar
• Zervas E, Samitas K, Papaioannou AI, et al. An algorithmic approach for the treatment of severe uncontrolled asthma. ERJ Open Res. 2018;4(1):00125–2017. doi:10.1183/23120541.00125-201729531957
   PubMedGoogle Scholar
• Nachef Z, Krishnan A, Mashtare T, et al. Omalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: a network meta-analysis. J Asthma. 2018;55(1):89–100. doi:10.1080/02770903.2017.130654828459601
   PubMed Web of Science ®Google Scholar
• Chapman KR, Albers FC, Chipps B, et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019;74(5):999–1003. doi:10.1111/all.1385030481388
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Xolair, INN-omalizumab Xolair powder and solvent for solution for injection: summary of product characteristics. 2012.
   Google Scholar
• Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 1997;155(6):1828–1834.9196082
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184–190. doi:10.1067/mai.2001.11788011496232
   PubMed Web of Science ®Google Scholar
• Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254–261. doi:10.1183/09031936.01.0009210111529281
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34(4):632–638. doi:10.1111/cea.2004.34.issue-415080818
   PubMed Web of Science ®Google Scholar
• Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of antiimmunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy. 2004;59:701–708. doi:10.1111/all.2004.59.issue-715180756
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy. (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309–316. doi:10.1111/all.2005.60.issue-315679715
   PubMed Web of Science ®Google Scholar
• Bousquet J, Siergiejko Z, Swiebocka E, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 2011;66:671–678. doi:10.1111/all.2011.66.issue-521255035
   PubMed Web of Science ®Google Scholar
• McKeage K. Omalizumab: a review of its Use in patients with severe persistent allergic asthma. Drugs. 2013;73:1197–1212. doi:10.1007/s40265-013-0085-423812924
   PubMed Web of Science ®Google Scholar
• Pelaia G, Vatrella A, Busceti MT, et al. Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments. Curr Drug Targets. 2015;16(2):171–178. doi:10.2174/138945011666614121912215725523898
   PubMed Web of Science ®Google Scholar
• Braunstahl GJ, Canvin J, Peachey G, et al. Healthcare resource utilization in patients receiving omalizumab for allergic asthma in a real-world setting. Biol Ther. 2014;4(1–2):57–67. doi:10.1007/s13554-014-0019-z25371373
   PubMedGoogle Scholar
• Katsaounou P, Buhl R, Brusselle G, et al. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma. Respir Med. 2019;150:51–62. doi:10.1016/j.rmed.2019.02.00330961951
   PubMed Web of Science ®Google Scholar
• Brusselle G, Michils A, Louis R, et al. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med. 2009;103:1633–1642. doi:10.1016/j.rmed.2009.06.01419619998
   PubMed Web of Science ®Google Scholar
• Braunstahl GJ, Chen CW, Maykut R, et al. The eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107(8):1141–1151. doi:10.1016/j.rmed.2013.04.01723721684
   PubMed Web of Science ®Google Scholar
• Barnes N, Menzies-Gow A, Mansur AH, et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma. 2013;50(5):529–536. doi:10.3109/02770903.2013.79041923574000
   PubMed Web of Science ®Google Scholar
• Bhutani M, Yang WH, Hébert J, et al. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: the ASTERIX Observational study. PLoS One. 2017;12(8):e0183869. doi:10.1371/journal.pone.018386928859150
   PubMed Web of Science ®Google Scholar
• Molimard M, de Blay F, Didier A, et al. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med. 2008;102:71–76. doi:10.1016/j.rmed.2007.08.00617920257
   PubMed Web of Science ®Google Scholar
• Korn S, Thielen A, Seyfried S, et al. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med. 2009;103:1725–1731. doi:10.1016/j.rmed.2009.05.00219515548
   PubMed Web of Science ®Google Scholar
• Tzortzaki EG, Georgiou A, Kampas D, et al. Longterm omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean “reallife” experience. Pulm Pharmacol Ther. 2012;25:77–82. doi:10.1016/j.pupt.2011.11.00422155001
   PubMed Web of Science ®Google Scholar
• Cazzola M, Camiciottoli G, Bonavia M, et al. Italian real-life experience of omalizumab. Respir Med. 2010;104(10):1410–1416. doi:10.1016/j.rmed.2010.04.01320483574
   PubMed Web of Science ®Google Scholar
• Menzella F, Galeone C, Formisano D, et al. Real-life efficacy of omalizumab after 9 years of follow-up. Allergy Asthma Immunol Res. 2017;9(4):368–372. doi:10.4168/aair.2017.9.4.36828497924
   PubMed Web of Science ®Google Scholar
• Alhossan A, Lee CS, MacDonald K, et al. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis. J Allergy Clin Immunol Pract. 2017;5(5):1362–1370. doi:10.1016/j.jaip.2017.02.00228351783
   PubMed Web of Science ®Google Scholar
• Deschildre A, Roussel J, Drumez E, et al. Omalizumab discontinuation in children with severe allergic asthma: an observational real-life study. Allergy. 2019;74(5):999–1003. doi:10.1111/all.2019.74.issue-530481388
   PubMed Web of Science ®Google Scholar
• Casale TB, Chipps BE, Rosén K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73(2):490–497. doi:10.1111/all.1330228859263
   PubMed Web of Science ®Google Scholar
• Canonica GW, Bartezaghi M, Marino R, et al. Prevalence of perennial severe allergic asthma in Italy and effectiveness of omalizumab in its management: PROXIMA – an observational, 2 phase, patient reported outcomes study. Clin Mol Allergy. 2015;13(1):10. doi:10.1186/s12948-015-0019-726155196
   PubMedGoogle Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–250. doi:10.1016/j.jval.2013.02.00223538175
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the Economic Evaluation of Health Care Programmes. 4th ed. Oxford University Press; 2015 ISBN: 9780199665877.
   Google Scholar
• AIFA. Guideline for the classification and management of observational studies on drugs. 3 20, 2008 Available from: http://www.agenziafarmaco.com/en. Accessed 1112, 2017.
   Google Scholar
• Reddel HK, Taylor DR, Bateman ED, et al. An official american thoracic society/european respiratory society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical v practice. Am J Respir Crit Care Med. 2009;1(180):59–99. doi:10.1164/rccm.200801-060ST
   Web of Science ®Google Scholar
• Colombo GL, Gaeta GB, Viganò M, et al. A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. Clinico Econ Outcomes Res. 2011;3:37–46. doi:10.2147/CEOR.S16655
   Google Scholar
• Cleemput I, Neyt M, Thiry N. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Int J Technol Assess Health Care. 2011;27(1):71–76. doi:10.1017/S026646231000119421262069
   PubMed Web of Science ®Google Scholar
• Raftery J. Review of NICE’s recommendations, 1999–2005. BMJ. 2006;332(7552):1266–1268. doi:10.1136/bmj.332.7552.126616735341
   PubMed Web of Science ®Google Scholar
• Italian Health Economics Association Associazione Italiana di Economia Sanitaria – AIES. Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. [Italian guidelines proposal on how to conduct economic evaluation studies of health programs]. Pharmacoecon Ital Res Articles. 2009;11:83–93. doi:10.1007/BF03320660
   Google Scholar
• Lucioni C, Ravasio R. Come valutare i risultati di uno studio farmacoeconomico? PharmacoEcon Ital Res Articles. 2004;3:121–130. doi:10.1007/BF03320630
   Google Scholar
• Messori A, Santarlasci B, Trippoli S, Vaiani M. Controvalore economico del farmaco e beneficio clinico: statodell’arte della metodologia e applicazione di un algoritmo farmacoeconomico. Pharmacoecon Ital Res Articles. 2003;5:53–67. doi:10.1007/BF03320605
   Google Scholar
• Ministero della Salute. (Italian Ministry of Health). Tariffe delle prestazioni di assistenza ospedaliera per acuti [DRG tariffs]. Gazzetta Ufficiale della Repubblica Italiana Serie N.23; Supplemento N.8 del 28 gennaio 2013.
   Google Scholar
• Ministero della Salute. (Italian Ministry of Health). Tariffe delle prestazioni di assistenza specialistica ambulatoriale. [inpatient tariffs]. Gazzetta Ufficiale della Repubblica Italiana Serie N.23; Supplemento N.8 del 28 gennaio. 2013.
   Google Scholar
• FARMADATI Italia software.
   Google Scholar
• Sweeney J, Brightling CE, Menzies-Gow A, et al. Clinical management and outcome of refractory asthma in the UK from the British thoracic society difficult asthma registry. Thorax. 2012;67:754–756. doi:10.1136/thoraxjnl-2012-20186922581823
   PubMed Web of Science ®Google Scholar
• Sweeney J, Patterson CC, Menzies-Gow A, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax. 2016;71:339–346. doi:10.1136/thoraxjnl-2015-20763026819354
   PubMed Web of Science ®Google Scholar
• Drummond MF, Schulpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford: Oxford University Press; 2005.
   Google Scholar
• Novelli F, Latorre M, Vergura L, et al. Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy. Pulm Pharmacol Ther. 2015;31:123–129. doi:10.1016/j.pupt.2014.09.00725281265
   PubMed Web of Science ®Google Scholar
• Abraham I, Alhossan A, Lee CS, et al. Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy. 2016;71(5):593–610. doi:10.1111/all.1281526644231
   PubMed Web of Science ®Google Scholar
• Sarnes E, Crofford L, Watson M, et al. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther. 2011;33:1413–1432. doi:10.1016/j.clinthera.2011.09.00921999885
   PubMed Web of Science ®Google Scholar
• Poetker DM, Reh DD. A comprehensive review of the adverse effects of systemic corticosteroids. Otolaryngol Clin North Am. 2010;43:753–768. doi:10.1016/j.otc.2010.04.00320599080
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan VH, Globe G, Schatz M. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol. 2018;141(1):110–116. doi:10.1016/j.jaci.2017.04.00928456623
   PubMed Web of Science ®Google Scholar
• Fardet L, Flahault A, Kettaneh A, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient’s opinion. Br J Dermatol. 2007;157:142–148. doi:10.1111/j.1365-2133.2007.07950.x17501951
   PubMed Web of Science ®Google Scholar
• Manson SC, Brown RE, Cerulli A, et al. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med. 2009;103:975–994. doi:10.1016/j.rmed.2009.01.00319372037
   PubMed Web of Science ®Google Scholar
• Barry LE, Sweeney J, O’Neill C, et al. The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis. Respir Res. 2017;18:129.28651591
   PubMed Web of Science ®Google Scholar
• Faria R, McKenna C, Palmer S. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis. Value Health. 2014;17(8):772–782. doi:10.1016/j.jval.2014.07.00925498772
   PubMed Web of Science ®Google Scholar
• Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol. 2007;120(5):1146–1152. doi:10.1016/j.jaci.2007.07.05517904628
   PubMed Web of Science ®Google Scholar
• Morishima T, Ikai H, Imanaka Y. Cost-effectiveness analysis of omalizumab for the treatment of severe asthma in Japan and the value of responder prediction methods based on a multinational trial. Value Health Reg Issues. 2013;2:29–36. doi:10.1016/j.vhri.2013.01.00729702848
   PubMedGoogle Scholar
• Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;13(1). doi:10.1002/14651858.CD003559.pub4/pdf
   Google Scholar
• Levy AN, García a Ruiz AJ, García-Agua Soler N, Sanjuan MVH. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective. J Asthma. 2015;52(2):205–210. doi:10.3109/02770903.2014.94147424995661
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Li Q, Bilir SP, et al. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States. Curr Med Res Opin. 2019 1–10. doi:10.1080/03007995.2019.1660539
   Web of Science ®Google Scholar
• Vennera MC, Valero A, Uría E, Forné C, Picado C. Cost-effectiveness analysis of omalizumab for the treatment of severe persistent asthma in real clinical practice in Spain. Clin Drug Investig. 2016;36(7):567–578. doi:10.1007/s40261-016-0402-2
   PubMed Web of Science ®Google Scholar
• Garrison LP, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007;10:326–335. doi:10.1111/j.1524-4733.2007.00186.x17888097
   PubMed Web of Science ®Google Scholar
• Ruggeri I, Bragato D, Colombo GL, Valla E, Di Matteo S. Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy. Clinicoecon Outcomes Res. 2012;4:375–382. doi:10.2147/CEOR.S3649923233808
   PubMedGoogle Scholar
• Nygaard L, Henriksen DP, Madsen H, et al. Appropriate selection for omalizumab treatment in patients with severe asthma? Eur Clin Respir J. 2017;4(1):1359477. doi:10.1080/20018525.2017.135947728815007
   PubMed Web of Science ®Google Scholar
• Braido F, Holgate S, Canonica GWC. From “blockbusters” to “biosimilars”: an opportunity for patients, medical specialists and health care providers. Pulm Pharmacol Ther. 2012;25:483–486. doi:10.1016/j.pupt.2012.09.00523010202
   PubMed Web of Science ®Google Scholar
• Said AA, Cushen B, Costello RW. Targeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money. Ther Adv Chronic Dis. 2017;8(2–3):31–45. doi:10.1177/204062231769049428348726
   PubMed Web of Science ®Google Scholar
• Del Negro RW, Pradelli L, Tognella S, et al. Cost-utility of add-on Omalizumab in difficult-to treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol. 2011;43(2):45–53.21608372
   PubMedGoogle Scholar
• Gibbison B, Griggs K, Mukherjee M, Sheikh A. Ten years of asthma admissions to adult critical care units in England and Wales. BMJ Open. 2013;3:e003420. doi:10.1136/bmjopen-2013-003420
   PubMed Web of Science ®Google Scholar